A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Human Acellular Vessel (HAV) with that of an Autogenous Arteriovenous Fistula (AVF) in Female Patients with End-Stage Renal Disease Requiring He- CLN-Pro-V012 - Pro00114567
Clinical Trial Grant
Administered By
Surgery, Vascular and Endovascular Surgery
Awarded By
Humacyte Global, Inc.
Start Date
April 24, 2024
End Date
April 30, 2032
Administered By
Surgery, Vascular and Endovascular Surgery
Awarded By
Humacyte Global, Inc.
Start Date
April 24, 2024
End Date
April 30, 2032